StockData
ADC Therapeutics SA logo

ADC Therapeutics SA (ADCT) stock

ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$1.34−0.07 (-4.96%)

Close on Nov 13, 2026Market cap $171.08MP/E –Yield –

ADC Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

ADC Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -97.7%. For fiscal 2025 it was -149.3%, against -184.4% the year before. The highest annual figure on record is -58.8% in fiscal 2022.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-149.3%+35.1
FY2024Dec 31, 2024-184.4%+54.2
FY2023Dec 31, 2023-238.6%−179.9
FY2022Dec 31, 2022-58.8%+712.9
FY2021Dec 31, 2021-771.6%+4330.9
FY2019Dec 31, 2019-5102.5%+5944.9
FY2018Dec 31, 2018-11047.5%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-66.1%+122.4
Q2 FY2026Jun 30, 2026-132.0%+102.3
Q1 FY2026Mar 31, 2026-121.1%+2.5
Q4 FY2025Dec 31, 2025-77.7%+114.1
Q3 FY2025Sep 30, 2025-188.5%+4.1
Q2 FY2025Jun 30, 2025-234.3%−67.5
Q1 FY2025Mar 31, 2025-123.6%+62.6
Q4 FY2024Dec 31, 2024-191.8%+46.3
Q3 FY2024Sep 30, 2024-192.6%+56.8
Q2 FY2024Jun 30, 2024-166.8%+38.8
Q1 FY2024Mar 31, 2024-186.2%+78.2
Q4 FY2023Dec 31, 2023-238.1%−223.1
Q3 FY2023Sep 30, 2023-249.4%−245.3
Q2 FY2023Jun 30, 2023-205.6%+195.8
Q1 FY2023Mar 31, 2023-264.4%−177.6
Q4 FY2022Dec 31, 2022-15.0%+354.1
Q3 FY2022Sep 30, 2022-4.1%+435.5
Q2 FY2022Jun 30, 2022-401.4%+1473.1
Q1 FY2022Mar 31, 2022-86.8%–
Q4 FY2021Dec 31, 2021-369.1%–
Q3 FY2021Sep 30, 2021-439.6%–
Q2 FY2021Jun 30, 2021-1874.5%–

More ADC Therapeutics figures

See a number that looks wrong?